Citadel Advisors
CSTL icon

Citadel Advisors’s Castle Biosciences CSTL Stock Holding History

Citadel Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.97M Sell
120,977
-245,379
-67% -$8.04M ﹤0.01% 5285
2025
Q4 		$14.3M Buy
366,356
+115,441
+46% +$3.72M ﹤0.01% 2771
2025
Q3 		$5.71M Sell
250,915
-637,600
-72% -$13M ﹤0.01% 4124
2025
Q2 		$18.1M Buy
888,515
+630,133
+244% +$11.7M ﹤0.01% 2264
2025
Q1 		$5.17M Sell
258,382
-576,130
-69% -$14.3M ﹤0.01% 3814
2024
Q4 		$22.2M Buy
834,512
+201,496
+32% +$6.14M ﹤0.01% 2056
2024
Q3 		$18.1M Sell
633,016
-60,369
-9% -$1.54M ﹤0.01% 2153
2024
Q2 		$15.1M Buy
693,385
+37,619
+6% +$838K ﹤0.01% 2307
2024
Q1 		$14.5M Buy
655,766
+327,017
+99% +$7.11M ﹤0.01% 2436
2023
Q4 		$7.09M Sell
328,749
-189,309
-37% -$3.33M ﹤0.01% 3304
2023
Q3 		$8.75M Buy
518,058
+461,775
+820% +$8.08M ﹤0.01% 2859
2023
Q2 		$772K Sell
56,283
-604,673
-91% -$12.3M ﹤0.01% 6998
2023
Q1 		$15M Buy
660,956
+109,641
+20% +$2.68M ﹤0.01% 2270
2022
Q4 		$13M Sell
551,315
-181,340
-25% -$4.2M ﹤0.01% 2463
2022
Q3 		$19.1M Buy
732,655
+102,059
+16% +$2.86M ﹤0.01% 1920
2022
Q2 		$13.8M Buy
630,596
+443,589
+237% +$10.3M ﹤0.01% 2273
2022
Q1 		$8.39M Buy
187,007
+89,121
+91% +$3.68M ﹤0.01% 3246
2021
Q4 		$4.2M Sell
97,886
-132,553
-58% -$6.93M ﹤0.01% 4648
2021
Q3 		$15.3M Buy
230,439
+170,434
+284% +$12M ﹤0.01% 2403
2021
Q2 		$4.4M Sell
60,005
-87
-0.1% -$5.75K ﹤0.01% 4713
2021
Q1 		$4.11M Buy
60,092
+50,103
+502% +$3.77M ﹤0.01% 4704
2020
Q4 		$670K Sell
9,989
-49,807
-83% -$2.7M ﹤0.01% 7578
2020
Q3 		$3.08M Sell
59,796
-1,606
-3% -$71.4K ﹤0.01% 3944
2020
Q2 		$2.31M Buy
+61,402
New +$2.1M ﹤0.01% 4316
2020
Q1 		– Sell
-8,900
Closed -$305K – 9655
2019
Q4 		$305K Sell
8,900
-21,775
-71% -$532K ﹤0.01% 7552
2019
Q3 		$555K Buy
+30,675
New +$680K ﹤0.01% 6567

Other funds holding CSTL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $3.72B AUM 162.29% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors's CSTL Position: Q1 2026 in Review

Citadel Advisors reduced its Castle Biosciences (CSTL) stake by 67% in Q1 2026, selling an estimated $8.04M and leaving 120,977 shares worth $2.97M. The position accounts for ﹤0.01% of the portfolio, ranked #5285.

Citadel Advisors first reported a position in CSTL in Q3 2019 and has held it in 26 quarters since. The position peaked at $22.2M in Q4 2024. 186 funds tracked by Wall St. Rank hold CSTL as of Q1 2026.

  • Citadel Advisors held 120,977 shares of Castle Biosciences worth $2.97M as of Q1 2026.
  • Citadel Advisors sold 245,379 Castle Biosciences shares in Q1 2026, an estimated $8.04M.
  • Castle Biosciences made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5285 holding.
  • Citadel Advisors first reported a position in Castle Biosciences in Q3 2019 and has held it in 26 quarters since.
  • Citadel Advisors's Castle Biosciences position peaked at $22.2M in Q4 2024.
  • 186 funds tracked by Wall St. Rank held Castle Biosciences as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.